Experience with denosumab (XGEVA®) for prevention of skeletal-related events in the 10 years after approval

Skeletal-related events (SREs) are complications of bone metastases and carry a significant patient and economic burden. Denosumab is a receptor activator of nuclear factor-κB ligand (RANKL) inhibitor approved for SRE prevention in patients with multiple myeloma and patients with bone metastases fro...

Descripción completa

Detalles Bibliográficos
Autores principales: Cadieux, Benoit, Coleman, Robert, Jafarinasabian, Pegah, Lipton, Allan, Orlowski, Robert Z., Saad, Fred, Scagliotti, Giorgio V., Shimizu, Kazuyuki, Stopeck, Alison
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8857591/
https://www.ncbi.nlm.nih.gov/pubmed/35242510
http://dx.doi.org/10.1016/j.jbo.2022.100416

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8857591/
https://www.ncbi.nlm.nih.gov/pubmed/35242510
http://dx.doi.org/10.1016/j.jbo.2022.100416

Ejemplares similares